Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

The GOLD 2023 and 2024 reports recommend that health professionals consider triple therapy (TT) entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), ...

All of them can make you feel breathless. Doctors use stages or grades to describe how severe your COPD is. This system is called the GOLD staging or grading system. Your grade will affect what ...

Credit: Getty Images. Patients with COPD who have the most severe airflow obstructions according to the GOLD strategy document had more exacerbations than those with less severe obstructions, and were ...

Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. It is a chronic disease that affects quality of life and mobility, and can lead to respiratory ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other brands), a class of hypnotic ...

Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada indicated. Among ...

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease affecting at least 15 million American adults. It’s also the fourth leading cause of disease-attributed death. This makes ...